NASDAQ : IVA
Inventiva S.A. — Key statistics
Healthcare · Biotechnology · France
Last price 3.73 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 882.39M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 838.96M |
| Enterprise Value | 808.43M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 236.28M |
| Shares Change (YoY) | +205.16% |
| Shares Change (QoQ) | +3.33% |
| Owned by Insiders (%) | 4.08% |
| Owned by Institutions (%) | 72.64% |
| Float | 179.98M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 299.00 |
| Forward PS | 210.08 |
| PB Ratio | 12.45 |
| P/TBV Ratio | 12.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 288.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.81 |
| Quick Ratio | 2.73 |
| Debt / Equity | 2.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.83 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -989.05% |
| Return on Assets (ROA) | -42.68% |
| Return on Invested Capital (ROIC) | -57.08% |
| Return on Capital Employed (ROCE) | -78.71% |
| Weighted Average Cost of Capital (WACC) | 11.66% |
| Revenue Per Employee | $32,252 |
| Profits Per Employee | -$3.25M |
| Employee Count | 87 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 718,611 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -12.26% |
| 50-Day Moving Average | 3.82 |
| 200-Day Moving Average | 4.88 |
| Relative Strength Index (RSI) | 53.80 |
| Average Volume (20 Days) | 2,806,793 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.15M |
| Short Previous Month | 8.35M |
| Short % of Shares Out | 3.65% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.90 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.81M |
| Gross Profit | 2.20M |
| Operating Income | -167.82M |
| Pretax Income | -282.30M |
| Net Income | -283.01M |
| EBITDA | -170.29M |
| EBIT | -167.82M |
| Loss Per Share | -$1.03 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 189.79M |
| Total Debt | 158.56M |
| Net Cash | 31.23M |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 67.41M |
| Book Value Per Share | 0.29 |
| Working Capital | 207.22M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -107.79M |
| Capital Expenditures | -399,497 |
| Depreciation & Amortization | -2.42M |
| Net Borrowing | 14.29M |
| Free Cash Flow | -108.19M |
| FCF Per Share | -$0.46 |
Margins
| Measure | Value |
|---|
| Gross Margin | 78.26% |
| Operating Margin | -5,980.94% |
| Pretax Margin | -10,060.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -205.16% |
| Shareholder Yield | -205.16% |
| Earnings Yield | -28.14% |
| FCF Yield | -12.90% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.20 |
| Price Target Difference | 316.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 165.52% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.88 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |